Clinical Trial: A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED)

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A Study of M-M-R(TM) II at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age

Brief Summary: The purpose of this study is to determine the mumps virus strength at the end of shelf-life (expiration date) of an approved vaccine.

Detailed Summary:
Sponsor: Merck Sharp & Dohme Corp.

Current Primary Outcome: Neutralizing antibodies to mumps at 6 weeks postvaccination [ Time Frame: 6 weeks postvaccination ]

Original Primary Outcome:

Current Secondary Outcome: Geometric mean titers to mumps by ELISA at 6 weeks and at 1 year postvaccination [ Time Frame: 6 weeks and 1 year postvaccination ]

Original Secondary Outcome:

Information By: Merck Sharp & Dohme Corp.

Dates:
Date Received: September 22, 2004
Date Started: February 1999
Date Completion:
Last Updated: October 22, 2015
Last Verified: October 2015